Technical Analysis for CELU - Celularity Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 3.38 | 5.30% | 0.17 |
CELU closed up 5.3 percent on Wednesday, April 24, 2024, on 46 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 200 DMA | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 200 DMA Resistance | Bearish | 5.30% | |
| Wide Bands | Range Expansion | 5.30% | |
| Oversold Stochastic | Weakness | 5.30% | |
| Lower Bollinger Band Walk | Weakness | 10.46% | |
| Wide Bands | Range Expansion | 10.46% | |
| Oversold Stochastic | Weakness | 10.46% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 3 hours ago |
| Up 5% | about 3 hours ago |
| Possible NR7 | about 5 hours ago |
| Possible Inside Day | about 5 hours ago |
| 200 DMA Resistance | about 8 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/20/2024
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
Sector: Industrials
Industry: Conglomerates
Keywords: Biotechnology Cancer Biology Immune System Stem Cell Cell Therapy Natural Killer Cell Lymphocytes Therapeutic Solutions
Classification
Sector: Industrials
Industry: Conglomerates
Keywords: Biotechnology Cancer Biology Immune System Stem Cell Cell Therapy Natural Killer Cell Lymphocytes Therapeutic Solutions
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.9 |
| 52 Week Low | 1.59 |
| Average Volume | 78,233 |
| 200-Day Moving Average | 3.33 |
| 50-Day Moving Average | 4.66 |
| 20-Day Moving Average | 4.39 |
| 10-Day Moving Average | 3.57 |
| Average True Range | 0.45 |
| RSI (14) | 35.06 |
| ADX | 30.05 |
| +DI | 15.89 |
| -DI | 32.20 |
| Chandelier Exit (Long, 3 ATRs) | 4.43 |
| Chandelier Exit (Short, 3 ATRs) | 4.33 |
| Upper Bollinger Bands | 6.22 |
| Lower Bollinger Band | 2.56 |
| Percent B (%b) | 0.22 |
| BandWidth | 83.25 |
| MACD Line | -0.50 |
| MACD Signal Line | -0.32 |
| MACD Histogram | -0.173 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.80 | ||||
| Resistance 3 (R3) | 3.79 | 3.64 | 3.73 | ||
| Resistance 2 (R2) | 3.64 | 3.53 | 3.65 | 3.71 | |
| Resistance 1 (R1) | 3.51 | 3.47 | 3.58 | 3.52 | 3.68 |
| Pivot Point | 3.36 | 3.36 | 3.39 | 3.37 | 3.36 |
| Support 1 (S1) | 3.23 | 3.25 | 3.30 | 3.24 | 3.08 |
| Support 2 (S2) | 3.08 | 3.19 | 3.09 | 3.05 | |
| Support 3 (S3) | 2.95 | 3.08 | 3.03 | ||
| Support 4 (S4) | 2.96 |
